{"name":"CytRx Corporation","slug":"cytrx","ticker":"CYTR","exchange":"OTC","domain":"cytrx.com","description":"CytRx Corp. is a biopharmaceutical research and development oncology company based in Los Angeles, California.","hq":"Los Angeles, CA","founded":0,"employees":"","ceo":"Steven A. Kriegsman","sector":"Biotech — Rare Disease / Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$18M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"CytRx Corporation Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"CytRx reported a net loss of $13.4 million for the fourth quarter and $43.6 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"CytRx Corporation Announces Collaboration with National Cancer Institute","summary":"CytRx entered into a collaboration with the National Cancer Institute to develop new cancer treatments.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQeWwtczR5U2JfM25JcXhTMzQwTzd6eVlLUW44dFp6RGpoUjJFYXdfaVhaMDNRTktxN2hnbmFTLTNxLVgwNW5xanIxZ2RTcDE1UVg5YmFPWFdzYWVEaEY5emxCOXlLeG94blR5S0NsN0FqMkZUU1daU2Jfb0xTSTQ5TkVKb005SFNrTF9INXhjY2tXSjdGSHA0NzlNMjQ?oc=5","date":"2022-09-26","type":"pipeline","source":"Fierce Pharma","summary":"CytRx guns for a reset, rebranding as LadRx after a tough few years and a CEO change in January - Fierce Pharma","headline":"CytRx guns for a reset, rebranding as LadRx after a tough few years and a CEO change in January","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQbG1XR3FFXzhUZlMxYXRUWGhXb0poLUVYS05MaERNT2JXZ0RjYk9VYXRyLWNkVFJVdTV4WW5vV3NSZGgwUjlwMjVobl9lUFZJMTRMYmxPclZ6ME5reldna0RLcWVjYVlIZkQ5SS02M1NqaTlLTVpBaVhLcEFxWFA1V0pKN2ljR2ZmX1RFWFE5RGZKaXowcWlrbW1hQzB0SzBhM25oU3R6NXBSV09KRERtdHpqRllMbGhFRmpF?oc=5","date":"2019-08-09","type":"earnings","source":"PR Newswire","summary":"CytRx Corporation Reports Second Quarter 2019 Financial Results - PR Newswire","headline":"CytRx Corporation Reports Second Quarter 2019 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNZG1UYy1qUEQ2OTdZSHJ6aUlMb1BUV3dpZDV4MDNTU2VXYTZrWHo1M3BLUFhsMFBGYnIxTkJtQk0wcXB6azh2TXo3LTQ3enlpeXpPdFFkYllvbVZHcVZLYVVVS19VLWJNVTUweTBHRlowLXRfck1BTk9EMVZySDBreGJicGJLZHBLR2l3aEd3YmJmdw?oc=5","date":"2017-10-23","type":"pipeline","source":"ryortho.com","summary":"Medovex – From the Dean of Healthcare Entrepreneurism – at NASS - ryortho.com","headline":"Medovex – From the Dean of Healthcare Entrepreneurism – at NASS","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Amgen","Bristol-Myers Squibb","Celgene"],"therapeuticFocus":["Oncology","Rare Diseases"],"financials":null,"yahoo":null}